Neoadjuvant treatment for rectal cancer

xlomafota13 shared this article with you from Inoreader Neoadjuvant treatment for rectal cancer Via Association française pour l'étude du cancer Bull Cancer. 2021 Jun 14:S0007-4551(21)00201-0. doi: 10.1016/j.bulcan.2021.03.018. Online ahead of print. ABSTRACT The management of patients with locally advanced rectal cancer has improved significantly in the past few years with preoperative radiotherapy (RT) and total mesorectal excision. The rate of local recurrence is now around 5 % while the risk of metastatic recurrence has not been reduced which is about 30 %. The benefit of adjuvant chemotherapy remains questionable apart from patients with ypN+tumor after preoperative chemoradiotherapy (CRT) for whom FOLFOX is an option. In recent years, several therapeutic trials have evaluated the benefit of extending the time between the end of RT and surgery and/or the benefit of neoadjuvant chemotherapy, administered as induction (before RT) or in consolidation (after RT and before surgery). The first results of two positive phase 3 trials, PRODIGE 23 and RAPIDO, have been reported in 2 020. The two regimens evaluated in these trials are markedly different but have shown that neoadjuvant chemotherapy significantly reduces the risk of distant metastasis. Current developments largely related to a de-escalation of therapy: organ conservation according to a "Watch and Wait" strategy or local resection of the scar, administration of neoadjuvant chemotherapy without RT. These therapeutic strategies have not yet been validated but should be in the news tomorrow. The purpose of this review is to present recent data reported in patients with locally advanced rectal cancer. PMID:34140155 | DOI:10.1016/j.bulcan.2021.03.018 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.